TriGemX Bio (TGEM) via TCGX Acq (TCGX) deck
A clinical-stage biotechnology company developing first-in-class small molecule TRPM8 channel blockers for migraine via a public merger.
A clinical-stage biotechnology company developing first-in-class small molecule TRPM8 channel blockers for migraine via a public merger.
%20via%20TCGX%20Acq%20(TCGX)%20deck){kind=link}